A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans.
The treatment, developed by Cornell biomedical engineers, is a synthetic version of a naturally occurring joint lubricant that binds to the surface of cartilage in joints and acts as a cushion during high-impact activities, such as running.
“When the production of that specific lubricant goes down, it creates higher contact between the surfaces of the joint and, over time, it leads to osteoarthritis,” said David Putnam, a professor in the College of Engineering with appointments in the Meinig School of Biomedical Engineering and the Smith School of Chemical and Biomolecular Engineering.
Putnam is senior author of “Boundary Mode Lubrication of Articular Cartilage With a Biomimetic Diblock Copolymer,” published June 4 in Proceedings of the National Academy of Sciences, USA. Zhexun Sun, a postdoctoral researcher in Putnam’s lab, is the paper’s first author.
The study focuses on a naturally occurring joint lubricant called lubricin, the production of which declines following traumatic injuries to a joint, such as a ligament tear in a knee.
The knee is lubricated in two ways – hydrodynamic mode and boundary mode.
Hydrodynamic mode lubrication occurs when the joint is moving fast and there isn’t a strong force pushing down on it. In this mode, joints are lubricated by compounds like hyaluronic acid (HA) that are thick and gooey, like car oil. There are numerous HA products on the market, approved by the Food and Drug Administration, for treating hydrodynamic mode lubrication disorders.
But HA is ineffective when strong forces are pushing down on the joint, such as those that occur during running or jumping. In these instances, thick gooey HA squirts out from between the cartilage surfaces, and boundary mode lubrication is necessary. Under these forces, lubricin binds to the surface of the cartilage. It contains sugars that hold on to water, to cushion hard forces on the knee.
In the paper, the researchers describe a synthetic polymer they developed that mimics the function of lubricin and is much easier to produce. “We are in clinical trials, with dogs that have osteoarthritis, with our collaborators at Cornell’s College of Veterinary Medicine,” Putnam said.
Those collaborators – Ursula Krotscheck and Kei Hayashi, both associate professors in the Section of Small Animal Surgery in the Department of Clinical Sciences – use a force plate to measure the efficacy of the treatments. The force plate quantifies the amount of force that a dog exerts with each paw, to measure whether they are favoring one paw over another.
“Once we finalize the efficacy study in dogs, we will be in a very good position to market the material for veterinary osteoarthritis treatment,” Putnam said. From there, the human market for a lubricin substitute should follow, just as HA has been made available for human use, mainly in knees.
The Latest on: Osteoarthritis
The Latest on: Biomechanics
via Google News
The Latest on: Osteoarthritis
- Ferring Pharmaceuticals Secures Patient Access to EUFLEXXA ® with Blue Cross Blue Shield of Michiganon November 18, 2019 at 4:06 pm
Medicare Advantage and Commercial formularies to include EUFLEXXA, hyaluronic sodium, as a co-preferred HA for osteoarthritis knee pain Ferring Pharmaceuticals today announced that Blue Cross Blue ...
- Dealing with osteoarthritison November 18, 2019 at 3:07 pm
As the most common form of arthritis, osteoarthritis (OA) affects 20% of people over the age of 50 globally. Also known as degenerative joint disease, OA can also affect people in their 20s or 30s.
- Opioids only modestly improve pain relief, function in OA, not QoLon November 18, 2019 at 1:37 pm
ATLANTA — Among patients with osteoarthritis, opioids demonstrated only moderate benefit for pain and function, while contributing no notable benefit for quality of life or depression compared with ...
- Exercise good for those with arthritison November 18, 2019 at 6:25 am
But what about people tormented with the pain and stiffness of osteoarthritis, particularly in the knees and hips? What are they supposed to do? There was an era when ethical medical practice demanded ...
- Seven approaches you may not have thought of to treat osteoarthritison November 18, 2019 at 5:20 am
As many as 8.75 million in the UK have been diagnosed with osteoarthritis, but plenty of others have not yet seen a doctor. No-one wants to have their lifestyle curtailed so here are a few different ...
- How to treat hip osteoarthritison November 15, 2019 at 11:07 pm
Osteoarthritis, sometimes called "wear and tear" arthritis, is a common degenerative condition. Doctors can treat osteoarthritis with medication and surgery. People can also manage their symptoms with ...
- Osteoarthritis Care Gets a Makeover With New Recommendationson November 15, 2019 at 1:25 pm
Osteoarthritis (OA) is the most common form of arthritis. Known as the “wear and tear” disease, this degenerative joint condition affects more than 30 million adults nationwide, according to the ...
- 2019 Osteoarthritis Therapeutics Market- Sanofi, Horizon Therapeutics, Johnson & Johnson, GlaxoSmithKline Plc and moreon November 14, 2019 at 1:42 am
Nov 14, 2019 (The Expresswire) -- Osteoarthritis Therapeutics Market Report including industry Overview, Country Analysis, Key Trends, Key Retail Innovations, Competitive Landscape and Sector Analysis ...
- Pain Management: Losing your grip with osteoarthritison November 11, 2019 at 3:54 pm
Furthermore, it took her about 20 minutes every morning for her fingers to become limber. Like Kathy, about 75 percent of women and 50 percent of men are affected with nodal osteoarthritis by age 70.
- Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammalson November 11, 2019 at 10:39 am
Israeli biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No.
via Bing News